PXL 770

Drug Profile

PXL 770

Alternative Names: PXL-770

Latest Information Update: 23 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Poxel
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Hepatoprotectants
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-alcoholic steatohepatitis; Type 2 diabetes mellitus

Most Recent Events

  • 18 Jul 2018 Poxel intends to file an IND application with the US FDA in (country) for Type 2 diabetes mellitus in second half of 2018
  • 18 Jul 2018 Adverse events, pharmacokinetics and drug interaction data from a phase I trial in Type 2 diabetes mellitus released by Poxel
  • 27 Feb 2018 Pharmacodynamics data from a preclinical studies in Non alcoholic steatohepatitis (NASH) released by Poxel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top